Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective

Metabolic dysfunction-associated steatohepatitis (MASH) is emerging as a leading cause of cirrhosis, hepatocellular carcinoma, and liver-related mortality worldwide. Among the most advanced pharmacologic candidates are resmetirom, a highly liver-selective thyroid hormone receptor-β (THR-β) agonist,...

Ausführliche Beschreibung

Bibliografische Detailangaben

1. Verfasser:	Ralf Weiskirchen
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Open Exploration 2025-10-01
Schriftenreihe:	Exploration of Drug Science
Schlagworte:	masld therapy drugs thyroid hormone receptor-β agonist glp-1 receptor agonist
Online-Zugang:	https://www.explorationpub.com/uploads/Article/A1008132/1008132.pdf
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!